NuSep licences gels

By Dylan Bushell-Embling
Wednesday, 17 September, 2008

NuSep [ASX: NSP] will accept an offer to license its electrophoresis gel business.

The third party had offered to acquire NuSep's gels business outright or to license the technology.

It was decided that licensing the technology would provide the best return for shareholders, the company said.

The licensing deal should give NuSep enough money to fund this commercialisation of its MF10 and SpermSep separation instruments without any additional fund-raising, and will likely generate an ongoing royalty fee.

NuSep also supplies research grade biological products such as human IgG and albumin.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd